Fangsheng Pharmaceutical: Hunan Kexin plans to sell 51% of its subsidiary hospital Changsha Kexin
I'm PortAI, I can summarize articles.
Fangsheng Pharmaceutical announced that Hunan Kexin decided to sell 51% of Changsha Kexin's equity to INKON Life for 357 million yuan, and will transfer 29% and 20% of the equity in installments based on performance commitments. Hunan Kexin plans to pay the sale proceeds in three installments through equity repurchase, with an expected repurchase amount of 154.6834 million yuan. Fangsheng still has 98.5 million yuan of unpaid capital contributions, and it is expected that the first installment of the repurchase can recover 87.6055 million yuan, covering 88.94% of the unpaid amount
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments